---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-111045"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:53:42.812228+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics increases ATM offering capacity from $50M to $100M

## Summary
- Amendment No. 1 to Sales Agreement raises aggregate offering price limit from $50M to $100M.
- Sales agent remains Guggenheim Securities, LLC; shares sold at market prices under Rule 415.
- Company filed a prospectus supplement with the SEC on November 14, 2025, covering the increase.
- Legal opinion on share validity from Sheppard Mullin filed as Exhibit 5.1.

## SEC filing metadata
- accession: 0001213900-25-111045
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390025111045/0001213900-25-111045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390025111045/ea0265675-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-111045
- JSON: https://secwatch.observer/filing/0001213900-25-111045.json
- Plain text: https://secwatch.observer/filing/0001213900-25-111045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.